Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytobiological studies in multiple myeloma.

A Pileri1, M Massaia, U Dianzani

  • 1Cattedra di Ematologia, Università di Torino, Italia.

Acta Haematologica
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Cutaneous involvement in multiple myeloma. A rare entity.

Clinical case reports·2025
Same author

Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: A systematic review.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

BCL-2 expression in primary cutaneous follicle center lymphoma is associated with a higher risk of cutaneous relapses: A study of 126 cases.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same journal

Progression-free survival effect sizes in randomized controlled trials of targeted cancer therapies with positive outcomes.

Acta haematologica·2026
Same journal

Dapagliflozin in Patients with homozygous β-Thalassemia and Albuminuria.

Acta haematologica·2026
Same journal

Efficacy of second-generation FLT3 inhibitors in FLT3-mutated AML: A meta-analysis of randomized controlled trials.

Acta haematologica·2026
Same journal

Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter study.

Acta haematologica·2026
Same journal

Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection.

Acta haematologica·2026
Same journal

Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies.

Acta haematologica·2026
See all related articles

Multiple myeloma (MM) is a heterogeneous cancer. New clinical, kinetic, and immunological markers, including beta 2-microglobulin and 5' nucleotidase activity, help identify patient subgroups and guide therapeutic strategies.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma (MM) exhibits significant heterogeneity in patient survival.
  • Existing prognostic factors like beta 2-microglobulin (beta 2-M) reflect tumor burden but do not fully capture disease variability.
  • Monoclonal gammopathy of undetermined significance (MGUS) requires differentiation from early-stage MM.

Purpose of the Study:

  • To explore heterogeneity in multiple myeloma (MM) using clinical, kinetic, and immunological parameters.
  • To identify novel prognostic markers for MM patient stratification and therapeutic strategy development.
  • To differentiate between MGUS and early-stage MM.

Main Methods:

  • Clinical evaluation of beta 2-microglobulin (beta 2-M) levels across disease stages.

Related Experiment Videos

  • Kinetic studies using [3H]thymidine or 5-bromo-2-deoxyuridine incorporation to assess bone marrow plasma cell proliferation (labeling index, LI).
  • Immunological assessment of 5' nucleotidase (5'NT) enzymatic activity in peripheral blood lymphocytes and characterization of T cell subpopulations.

    • Main Results:

    • Beta 2-microglobulin (beta 2-M) showed a linear increase from stage I to III MM, with no clear cutoff from MGUS.
    • No correlation was found between beta 2-M and labeling index (LI), indicating distinct prognostic information.
    • MGUS consistently had LI < 1%, distinguishing it from MM. Patients with LI > 2% had reduced survival; early responders (LI > 2%, >50% M component decrease in 3 months) had ~10-month median survival.
    • A decrease in 5' nucleotidase (5'NT) activity was observed in poor-prognosis MM patients, linked to an expansion of activated suppressor T cells (OKM1+, DR+).

    Conclusions:

    • Clinical, kinetic, and immunological studies reveal distinct patient subgroups within MM.
    • Labeling index (LI) and 5' nucleotidase (5'NT) activity serve as valuable prognostic indicators.
    • These novel parameters can inform future therapeutic strategies for multiple myeloma.